University of Leeds researchers have taken a significant step in direction of producing a extra inexpensive and lower-risk polio vaccine utilizing virus-like particles (VLPs). These particles mimic the outer protein shell of poliovirus, however are empty inside. This means there isn’t a threat of an infection, however the VLP nonetheless causes the immune system to reply.
Now, an analysis mission led by Professor David Rowlands, Emeritus Professor of Molecular Virology on the University of Leeds, has examined the effectiveness of utilizing totally different yeast, insect, mammalian and plant cells as expression methods to generate VLPs.
In a paper revealed in Nature Communications, the findings present that VLPs produced in each yeast and insect cells can carry out equally or higher than the present inactivated polio vaccine (IPV), which creates an immune system response by utilizing a killed model of the poliovirus. The paper is titled “Recombinant expression methods for manufacturing of stabilised virus-like particles as next-generation polio vaccines.”
Professor Nicola Stonehouse is Chair in Molecular Biology on the University of Leeds School of Molecular and Cellular Biology and one of many senior authors on the paper. Professor Stonehouse mentioned, “Any vaccine is simply as efficient because the variety of kids that it reaches.
“The key’s to make vaccines universally accessible, as all kids have a proper to be protected against ailments equivalent to polio, regardless of where they reside. Ultimately, VLPs would considerably contribute to vaccine fairness.
“Thanks to analysis like this, we’re already working with business companions to supply the following technology of polio vaccines. Although we do not but know when these will likely be broadly accessible, we’re getting a lot nearer to a polio-free future.”
Today’s polio vaccines
Currently, IPV is comparatively costly to supply as a result of it requires excessive ranges of bio-containment to reduce the danger of leaks of reside poliovirus, which may end in outbreaks. VLPs are non-infectious and wouldn’t must be dealt with underneath such stringent bio-safety circumstances.
Oral polio vaccine (OPV), which comprises reside however weakened vaccine-virus, can be utilized in vaccination towards polio.
Future polio vaccines
However, as soon as all remaining strains of untamed poliovirus have been efficiently eradicated, OPV use might want to cease to remove a small threat of circulating variant poliovirus that may be related to its use.
In populations where massive numbers of persons are unvaccinated and sewage disposal is poor, such strains may cause an outbreak via contact with feces, typically through contaminated water.
At this time, IPV would be the solely polio vaccine accessible to populations, however costly manufacturing procedures make it unaffordable for lower-income nations.
Non-infectious VLPs are simpler to supply than present IPVs and analysis has proven they’re extra temperature-stable, due to genetic alteration of the outer shell. As they’re non-infectious, this implies they are going to be cheaper to supply, serving to to enhance equitable entry to vaccination.
Dr. Martin Eisenhawer is the WHO focal mark for the event of Polio VLPs and the VLP consortium led by the University of Leeds. Dr. Eisenhawer mentioned, “The WHO, when taking a look at analysis and improvement priorities for brand spanking new technology polio vaccines, has early on recognized VLPs as a know-how that could possibly be a perfect software, particularly for the post-eradication interval, with the goal for polio VLPs to be finally produced as a really value efficient and protected vaccine by creating nation producers for the good thing about a worldwide provide.
“Through an intensive collaboration with the analysis consortium, vaccine producers and the Global Polio Eradication Initiative (GPEI), we’re approaching this aim with the brand new developments.
“This analysis reveals {that a} vital new polio vaccine resolution is on the horizon. It can be a vital new software to not solely obtain however maintain world polio eradication, and guarantee—in an equitable method—that no youngster wherever will ever once more be paralyzed by any poliovirus. It is about making certain that after polio is eradicated, it is going to keep eradicated.”
The worldwide analysis collaboration additionally included researchers from the University of Oxford, the Medicines and Healthcare merchandise Regulatory Agency (MHRA), the John Innes Center, The Pirbright Institute, the University of Florida and the University of Reading. The structural information was collected utilizing a cryo-electron microscope at Diamond Light Source.
VLPs are already utilized in vaccines for hepatitis B and human papillomavirus (HPV)—and researchers have been working for over a decade to use this profitable know-how to assist eradicate polio.
The subsequent technology of polio vaccinations are more likely to be produced in yeast or insect cells, because the analysis confirmed these have been efficient when examined on rats and mice. These cell expression methods are additionally favored by corporations and are used for present vaccinations, attributable to their low value.
Dr. Lee Sherry was one among 4 lead authors on the paper whereas working on the University of Leeds. Dr. Sherry, who now holds a place on the University of Glasgow, mentioned, “Following the success of utilizing VLP vaccines in stopping hepatitis B and HPV-related ailments, it is rather thrilling to see this analysis being taken ahead by industrial companions as a safer vaccine manufacturing technique as we transfer in direction of a polio-free world.”
More data: Lee Sherry et al, Recombinant expression methods for manufacturing of stabilised virus-like particles as next-generation polio vaccines, Nature Communications (2025). DOI: 10.1038/s41467-025-56118-z